A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients with Platinum Refractory Extensive-Stage Small-Cell Lung Cancer 

Trial Identifier: D419QC00002
Sponsor: AstraZeneca
NCTID:: NCT02937818
Start Date: November 2016
Primary Completion Date: June 2020
Study Completion Date: December 2023
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English version
German Translation
Hungarian Translation
Polish Translation
Russian Translation
Spanish Translation

Trial Locations

Country Location
DE Gauting, DE, 82131
ES Sevilla, ES, 41009
ES Valencia, ES, 46009
HU Kecskemét, HU, 6000
HU Miskolc, HU, 3529
HU Székesfehérvár, HU, 8000
HU Törökbálint, HU, 2045
PL Poznań, PL, 60-569
PL Warszawa, PL, 02-781
UA Dnipro, UA, 49102
UA Ivano-Frankivsk, UA, 76018
UA Sumy, UA, 40022